Phosphorylated TAU217
3 papers1 finding
- Humans3
Effects
1Gait speed
downin humans1
1 study
Gait speed
downin humans1
Phosphorylated TAU217 decreases gait speed in humans (β: -0.010, 95% CI: -0.015; -0.005).
Humanshighest vs lowest quartile15 yearsn = 1,665
Journal of cachexia, sarcopenia and muscle1 Aug 2026
Latest
10 in 12 monthsPsyArXiv
Telephone-administered semantic fluency task in older adults without dementia in relation to in-person testing and plasma phosphorylated tau-217
Preprint: cross-sectional study of 200 peopleSemantic fluency
Alzheimer's & Dementia
Longitudinal plasma phosphorylated tau217 classification and the association with Alzheimer's disease progression
Cohort study of 2,117 peopleAlzheimer's disease
Alzheimer's & Dementia
Plasma GFAP modifies the association of depressive symptoms with cognitive function: A population-based study
Cross-sectional study of 11,059 peopleDepression
Journal of Cachexia, Sarcopenia and Muscle
Blood Biomarkers of Alzheimer's Disease and Gait Speed Trajectories in Community-Dwelling Older Adults: A Cohort Study
Cohort study of 1,665 peopleGait speed
Journal of Geriatric Psychiatry and Neurology
Plasma Biomarkers and Clinical Indicators for Identifying Mild Cognitive Impairment in Older Adults With Psychiatric Disorders
Cross-sectional study in peopleMild cognitive impairment
AAIC 2025 Abstract
Using Plasma p ‐tau217 to Define Cognitive Resilience in an Elective Hip and Knee Surgery Cohort
Study in peopleBiomarkers
AAIC 2025 Abstract
Detecting and monitoring longitudinal pathological and clinical changes of Alzheimer's disease using plasma p ‐Tau217
Study in peopleBiomarkers
AAIC 2025 Abstract
Association of Plasma Biomarkers of Alzheimer's Disease with Incident Tau PET Positivity
Study in peopleBiomarkers
AAIC 2025 Abstract
Plasma biomarkers of Alzheimer's disease and cognition in a population‐based sample
Study in peopleBiomarkers